MPS Pharmaa Limited (formerly Advik Laboratories Limited) reported a standalone net loss of ₹23.80 lakh for the quarter ended June 30, 2026, widening from a loss of ₹22.01 lakh in the corresponding period of FY25. The pharmaceutical formulations company recorded zero revenue from operations during the quarter, continuing its operational hiatus while awaiting regulatory approvals.

The Board of Directors approved the unaudited financial results on August 13, 2026. The company’s total expenses for the quarter stood at ₹23.80 lakh, driven primarily by employee benefit expenses of ₹14.36 lakh and other expenses of ₹5.88 lakh. Depreciation and amortisation accounted for ₹3.51 lakh, while finance costs remained negligible at ₹0.06 lakh.

Operational Status and Regulatory Hurdles

The absence of revenue stems from the pending renewal of the company’s Drug Manufacturing Licences with the Food & Drugs Administration (FDA), Panchkula. The management stated that the applications are under consideration and expressed confidence in restarting business operations soon, citing ongoing discussions with prospective buyers. However, the auditor’s report included an emphasis of matter regarding the lack of revenue from operations during the quarter.

Additionally, the company faces listing fee arrears with the Bombay Stock Exchange (BSE). MPS Pharmaa has not paid its Annual Listing Fees since FY22, leading to trading restrictions. BSE has permitted trading only on a Trade-for-Trade basis, limited to the first trading day of every week, until outstanding dues are cleared. Management indicated it is arranging funds to settle these payments.

Auditor’s Qualified Conclusion

Nemani Garg Agarwal & Co., the independent auditors, issued a qualified conclusion on the quarterly results due to two key observations:

• Unverified Investments: The company recorded an investment of ₹53.80 lakh in unquoted equity shares at acquisition cost but failed to determine fair value as required by Ind AS. Physical verification was not possible as share certificates were misplaced during record shifting, and requests for duplicates from investee companies have gone unanswered.
• Stalled Capital Work-in-Progress: Capital work-in-progress valued at ₹2.12 crore remains stalled. While management views the suspension as temporary and believes no impairment provision is needed, auditors noted that technical evaluation is required to assess potential write-offs.

What the Numbers Show

The financial data reveals a significant divergence between revenue generation and cost structure. With zero operating income, the entire expense burden of ₹23.80 lakh flowed directly to the bottom line, resulting in a pre-tax loss of identical magnitude. Notably, employee benefits constitute approximately 60% of total quarterly expenses (₹14.36 lakh out of ₹23.80 lakh), indicating that fixed personnel costs remain a primary drain on resources despite the lack of commercial activity. This highlights the challenge of maintaining operational readiness without corresponding cash inflows from sales.

MPS Pharmaa Limited reported a net loss of ₹102 lakh for the financial year ended March 31, 2026, as the company continued to record zero income from operations. The pharmaceutical firm, which has been without operational income for an extended period, saw its total expenses rise to ₹109.35 lakh for the year, primarily driven by employee benefit costs and the write-off of stores and spares. The company's net worth contracted to ₹6.85 lakh from ₹108.07 lakh in the previous year, reflecting the continued financial strain.

The Board of Directors approved the standalone audited financial results for the quarter and year ended March 31, 2026, during a meeting held on May 28, 2026. The filing was submitted to the BSE Limited pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015. Alongside the results, the company disclosed a statement of impact of audit qualifications, highlighting significant issues raised by the statutory auditors, M/s Nemani Garg Agarwal & Co.

Auditor's Observations and Management Response

The auditors issued a qualified opinion, citing two primary areas of concern. First, the company recorded investments costing ₹53.80 lakh at acquisition value without determining fair value as required by Ind AS. The auditors stated they were unable to comment on the physical existence or value of these investments because the share certificates were lost during a record shift and physical verification was not possible. Management explained that requests for duplicate certificates to investee companies have gone unanswered.

Second, capital work in progress amounting to ₹2.41 crore has been stalled. The auditors noted that the physical condition of these assets requires technical evaluation to determine potential impairments. However, management contends the suspension is temporary and that the assets are not obsolete, asserting that construction activities will resume soon and no provision is required.

Financial Performance and Key Metrics

The company's financial results for the year show a deterioration in its financial position. Total income was limited to other income of ₹3.56 lakh, down from ₹4.77 lakh in the previous year. Employee benefit expenses increased to ₹53.31 lakh from ₹52.47 lakh, while finance costs rose to ₹0.08 lakh. Notably, the company wrote off stores and spares worth ₹15.37 lakh due to deterioration and obsolescence caused by prolonged storage.

The basic and diluted earnings per share (EPS) for the year stood at a loss of ₹0.53, compared to a loss of ₹0.47 in the prior year. The paid-up equity share capital remained constant at ₹1,911.14 lakh. On the balance sheet, total assets decreased to ₹847.95 lakh as of March 31, 2026, from ₹933.19 lakh a year earlier. Current liabilities, primarily borrowings, stood at ₹818.85 lakh.

Governance and Compliance Updates

In a separate corporate governance update, the Board re-appointed M/s Sanghi & Co., Chartered Accountants, as the internal auditor for the financial year 2026-27 based on the Audit Committee's recommendation. The company also disclosed related party transactions for the half-year ended March 31, 2026, including unsecured loans received from promoter group member Peeyush Kumar Aggarwal and Omkam Global Capital Private Limited. Additionally, the company noted that its shares remain suspended on the BSE, with trading permitted only on a trade-for-trade basis once a week due to non-payment of annual listing fees since FY22.

Financial Results Summary